Market Currents
GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily...
-
Wednesday, September 26, 2012, 7:10 AM ETGlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily investigational medicine FF/VI for patients with chronic obstructive pulmonary disease has been accepted by the FDA, indicating the application is sufficiently complete to permit a substantive review.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
